Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Other Operating Expenses (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Other Operating Expenses for 15 consecutive years, with $5.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses fell 20.2% to $5.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $72.5 million, a 147.61% increase, with the full-year FY2024 number at $29.1 million, down 1.95% from a year prior.
  • Other Operating Expenses was $5.5 million for Q3 2025 at Harvard Bioscience, down from $5.9 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $54.3 million in Q1 2025 to a low of $5.5 million in Q3 2025.
  • A 5-year average of $9.7 million and a median of $7.4 million in 2022 define the central range for Other Operating Expenses.
  • Biggest YoY gain for Other Operating Expenses was 561.38% in 2025; the steepest drop was 20.2% in 2025.
  • Harvard Bioscience's Other Operating Expenses stood at $8.5 million in 2021, then fell by 10.79% to $7.6 million in 2022, then grew by 0.69% to $7.6 million in 2023, then decreased by 9.97% to $6.9 million in 2024, then fell by 20.4% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Other Operating Expenses are $5.5 million (Q3 2025), $5.9 million (Q2 2025), and $54.3 million (Q1 2025).